GOVERNMENT OF INDIA
SCIENCE AND TECHNOLOGY
LOK SABHA

UNSTARRED QUESTION NO:3143
ANSWERED ON:16.03.2016
R&D in Drug and Pharmaceutical Sector
Singh Shri Dushyant

Will the Minister of SCIENCE AND TECHNOLOGY be pleased to state:

(a) the details of the collaborative projects between industries and academic institutions, sanctioned by the Department of Science and Technology (DST) for Research and Development (R&D) in drug and pharmaceutical sector in the last three years;

(b) whether there has been a delay in the completion of many such sanctioned projects;

(c) if so, the details thereof and the steps taken by the Government to ensure their timely completion;

(d) the details of the outcomes of these projects which have partially or fully been funded by the Government;

(e) whether there has been inadequate project monitoring by DST which led to bad financial management of the Government funds and inefficient research; and

(f) if so, the details thereof along with the remedial measures taken by the Government?

Answer

MINISTER OF STATE IN THE MINISTRY OF SCIENCE AND TECHNOLOGY AND MINISTER OF STATE IN THE MINISTRY OF EARTH SCIENCES
(SHRI.Y. S. CHOWDARY)

(a) The details of the collaborative projects in drug and pharmaceutical sector for Research and Development (R&D) sanctioned by the Department of Science and Technology (DST) between industries and academic institutions in the last three years is enclosed as Annexure 1.

(b) & (c): The collaborative projects funded by DST are maximum of 3 years' duration. The R&D projects in drug and pharmaceutical sector have to undergo various phases such as drug discovery, pre-clinical and clinical trial which are resource intensive as well as time consuming. Every study has to be undertaken after taking necessary approvals like ethical clearance, compliance of ICMR guidelines, DCGI approval for clinical trials, etc. The government takes various steps to ensure timely completion by getting the progress report on time, constituting the monitoring committee of experts to monitor the progress. Based on the recommendations of the committee, DST and industry release their committed funds to academic institutions.

(d) The outcomes of these projects are mainly generating data for regulatory requirement such as safety, efficacy, stability, etc. However, some of the outcomes of the projects which have partially or fully been funded by the DST in drug and pharmaceutical sector are enclosed as Annexure 2.

(e) & (f): The projects are being monitored adequately by the experts in that area after receiving the technical and financial progress from the collaborative partners. The suggestions of the monitoring committee are communicated to project executives for compliance and implementing.

Annexure - 1

Collaborative Projects funded by DST in Drugs and Pharmaceutical Sector in the last three years
(Rs. in lakhs)
S.No Project Title Duration Name of the collaborating institutes/ industry Total approved cost DST share
Amount
released
2012-13

1. Product Development of Phyllanthus niruri and Glycine max(L.) Merr ., formulation for the management of Diabetes and associated complications, its Validation, Standardisation, Preclinical Toxicology and Pharmacological evaluation 3 yrs Sri Ramachandra University, Chennai.

Visva Bharati University, School of Life Science, Shantiniketan

East India Pharmaceutical Works Ltd., Kolkata 251.91 158.052 146.718
2. Scientific Validation of Safety, Protective and curative Efficacy of a Patented Folklore Medicine "Savliv" Developed for the

Management of Hepatic Disorders- A preclinical Study 2 yrs Sri Ramachandra University, Chennai

M/s. Harshul Ayur Pharma, Ramnagar 33.654 21.246 20.308
3. Genome wide association study to identify genetic variants conferring risk to cardiovascular disease − Indian population 3 yrs Alluri Sitaramaraju Academy of Medical Sciences, Eluru

M. S. University, Vadodara

Sri Ramachandra University, Chennai

Laila Pharmaceuticals Pvt Ltd.,
Vijayawada 214.852 179.3744 156.3276
2013-14

1. Development of Novel Mycotoxin binders for the management for mycotoxicosis in animal and human 1 yr Tamil Nadu Veterinary and Animal Sciences University, Chennai

M/s. Neospark Drugs and Chemicals Pvt. Ltd., Hyderabad 65.00 42.60 42.60
2. Development of targeted stealth nanocarrier for dual delivery in the treatment of oral cancer 3 yrs Sastra University, Thanjavur Orchid Research laboratories Ltd, Chennai 58.73 20.265 6.104

Annexure - 2
Some of the products developed under the DST funded projects in Drug and Pharmaceutical Sector

BONISTA - Teriparatide Injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis was developed by Virchow Biotech Pvt. Ltd., Hyderabad

ALQUIT - Ectoparasiticidal natural product developed for pet animals by Central Institute for Research on Goats, Mathura and M/s Natural Remedies Pvt. Ltd., Bangalore.

RHOCLONE - Anti-Rho-D Immunoglobulin Injection (Monoclonal) 300mcg developed for Hemolytic disease of the new born (HDN) by M/s Bharat Serums & Vaccines Limited, Mumbai.

ARTHAN - A novel topical aerosol spray developed for anti-arthritic using herbs by KMCH College of Pharmacy, Coimbatore and M/s Doctor Thangs Products, Coimbatore.

SYNRIAM − A new anti-malarial drug was developed by M/s Ranbaxy Laboratories Ltd.

AMPHOMUL − A drug for Visceral Leishmaniasis (Kala Azar) was developed by M/s Bharat Serums & Vaccines Ltd., Mumbai.

MYCIDAC - M/s Cadila Pharmaceuticals Ltd., Ahmedabad developed in combination with Pacletaxel Cisplatin for advanced Non Small Cell Lung Cancer (NSCLC).

*